Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Bile Duct Neoplasms 3Pancreatic Neoplasms 2Neoplasms 2Colorectal Neoplasms 2Venous Thromboembolism 1Supratentorial Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Sigmoid Neoplasms 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Glioma 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Erectile Dysfunction 1Endometrial Neoplasms 1Dyskinesias 1Diarrhea 1Chemotherapy-Induced Febrile Neutropenia 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Trastuzumab 594Paclitaxel 561Cyclophosphamide 545Docetaxel 478Capecitabine 387Letrozole 350Fulvestrant 310Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 175Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × Long-Term Synaptic Depression × Clear all
NCT07187752 2025-09-23

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

Shandong Cancer Hospital and Institute

Phase NA Not yet recruiting
1,039 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡